drugset / Trial / NCT00798720
Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer
Phase 2
Completed
18 enrolled
University of Wisconsin, Madison
Merck Sharp & Dohme LLC · collabMillennium Pharmaceuticals, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy of vorinostat and bortezomib in the third line treatment of advanced NSCLC, as well as to assess toxicity (including neuropathy) and tolerability of this regimen.
Timeline
- Start
- 2008-12
- Primary completion
- 2012-10
- Completion
- 2012-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | Intravenous |
| Subject | Vorinostat | Small molecule | 400 mg | Oral |